Patents by Inventor Wim Van Den Berg
Wim Van Den Berg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230235038Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: July 7, 2022Publication date: July 27, 2023Inventors: Franco E. Di Padova, Hermann GRAM, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20190270804Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: May 15, 2019Publication date: September 5, 2019Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 10344084Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 11, 2017Date of Patent: July 9, 2019Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20170355762Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: August 11, 2017Publication date: December 14, 2017Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 9765140Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2015Date of Patent: September 19, 2017Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20150152178Abstract: An IL-17 binding molecule, in particular .an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions or the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: February 18, 2015Publication date: June 4, 2015Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20140079719Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8617552Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: January 13, 2012Date of Patent: December 31, 2013Assignee: Novarts AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20120107325Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: January 13, 2012Publication date: May 3, 2012Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8119131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2010Date of Patent: February 21, 2012Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 7807155Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 4, 2005Date of Patent: October 5, 2010Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20100215666Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: February 18, 2010Publication date: August 26, 2010Inventors: FRANCO E. DI PADOVA, HERMANN GRAM, HANS HOFSTETTER, MARGIT JESCHKE, JEAN-MICHEL RONDEAU, WIM VAN DEN BERG
-
Publication number: 20090280131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: August 4, 2005Publication date: November 12, 2009Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20060121033Abstract: The C-type lectin DC-SIGN is absent in normal synovium but is highly expressed by CD68 positive macrophages in the synovium of rheumatoid arthritis patients. Accordingly, rheumatoid arthritis is diagnosed or treated by, respectively, assaying or blocking DC-SIGN. This can be accomplished by the use of agents, e.g., antibodies, which bind specifically to DCSIGN. Agents that bind to ICAM-3 are used to block inhibition of activation of macrophages by DC-SIGN-ICAM-3 interaction and cause inhibition of rheumatoid arthritis symptoms.Type: ApplicationFiled: September 19, 2003Publication date: June 8, 2006Inventors: Carl Figdor, Ruurd Torensma, Maria Petrus Leonardus Van Lent, Wim Van Den Berg
-
Publication number: 20030052796Abstract: System for controlling vehicles in a traffic network. The vehicles (4) comprise communication means (5), for communication, via a communication network (2), with a service mediator system (1), linking the vehicle's communication means to various servers (9a . . . i). The vehicle may comprise means (6) for exchanging data between the vehicles' software or hardware, while at least one of said servers comprises means for processing said data related to the vehicles' software or hardware, like fuel consumption and the vehicles' maintenance state. The vehicle's communication means may comprise location means, enabled for exchanging data relative to the vehicles' location to be used for planning and scheduling the use of the vehicles, route planning, billing vehicle related tax or insurance. One or more servers may be enabled to process requests for vehicle parking or for hiring alternative transportation room or means. One server may be enabled for automatic processing vehicle accidents.Type: ApplicationFiled: September 16, 2002Publication date: March 20, 2003Applicant: Koninklijke KPN N.V.Inventors: Johan Richard Schmidt, Wim Van Den Berg